Clinical trials
Small Cell Carcinoma clinical trials
Below are recruiting small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 782 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT07167459Enrolling by invitationPhase 2
Personalized radiation for early stage lung cancer
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07164170RecruitingPhase 2
Study of ABSK043 plus Glecirasib for advanced NSCLC
This trial tests a combination of two experimental drugs, ABSK043 and Glecirasib, for people with a specific type of advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination works better than standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07138755RecruitingPhase 2
PD-1, chemo, and adaptive radiation for stage 3 lung cancer
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
Changsha, HunanAges 18–75 - NCT07120698RecruitingPhase 2
MRD-guided sintilimab after surgery for NSCLC
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Guangzhou, GuangdongAges 28–75 - NCT07103395RecruitingPhase 2
Study of chemo, radiation, and dual immunotherapy for stage 3 lung cancer
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
Guangzhou, GuangdongAges 18–75 - NCT07096882RecruitingPhase 1
SDTM001 injection after lung cancer surgery
This trial tests an injection called SDTM001 as an extra treatment after surgery for people with non-small cell lung cancer (NSCLC). It aims to see if it can help prevent the cancer from coming back.
Chengdu, SichuanAges 18–70 - NCT07105176RecruitingPhase 1
TIL therapy for advanced lung cancer after first-line treatment
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06970795RecruitingPhase 1
Study of SYS6040 for advanced solid tumors
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Changchuan, JilinAges 18 years+ - NCT07089199RecruitingPhase 2
Treatment before surgery for stage 2–3 lung cancer
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
Jinan, ShandongAges 18–75 - NCT07087223RecruitingPhase 1/Phase 2
Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification
This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.
Neimeng, NeimengAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07077161RecruitingPhase 2
Skipping Cabozantinib Doses Instead of Reducing Them
This trial tests whether skipping a dose of cabozantinib instead of lowering the dose can help manage side effects while still controlling your kidney cancer. It is for people already taking cabozantinib who might need a break but want to stay on treatment.
Leiden, South HollandAges 18 years+ - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75 - NCT07070440RecruitingPhase 1/Phase 2
DZD6008 combination therapy for EGFR-mutated lung cancer
This trial tests a new combination treatment for people with advanced non-small cell lung cancer that has an EGFR mutation. It aims to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06598527RecruitingPhase 3
Radiation and immunotherapy before surgery for lung cancer
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07026474RecruitingPhase 3
Re-radiation plus immunotherapy for recurrent head and neck cancer
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
BerlinAges 18 years+ - NCT07016126RecruitingPhase 3
Study of D-BACE, chemo, and carlizumab for lung cancer
This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07003490Recruiting
Lung cancer surgery with removal of lymph nodes on the other side
This study looks at whether removing lymph nodes from the opposite side of the chest during surgery can help people with advanced lung cancer that has spread to the lymph nodes in the middle of the chest. It may offer a more thorough treatment for patients who are healthy enough for surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06494995RecruitingPhase 2
AK104 and low-dose radiation for advanced head and neck cancer
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06987734RecruitingPhase 2
Sugemalimab plus chemo before and after lung cancer surgery
This trial tests if adding the immunotherapy drug sugemalimab to standard chemotherapy before and after surgery can help people with stage II-IIIA non-small cell lung cancer. It aims to see if this combination reduces the chance of cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell carcinoma?
- Yes. Clin2 currently lists 782 recruiting small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.